<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04161547</url>
  </required_header>
  <id_info>
    <org_study_id>HA116201903/PRO I-MAD</org_study_id>
    <nct_id>NCT04161547</nct_id>
  </id_info>
  <brief_title>Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers</brief_title>
  <official_title>A Phase I, Ascending Multiple-dose Clinical Trial of CSPCHA115 Capsules to Evaluate the Tolerability and Pharmacokinetics in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, single-center, double-blind, ascending multiple-dose, placebo-controlled study&#xD;
      to evaluate the tolerability and pharmacokinetics of CSPCHA115 capsules in Chinese healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and incidence of subjects with Adverse Events (AEs)</measure>
    <time_frame>12 days after drug administration</time_frame>
    <description>To evaluate the safety and tolerability after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant symptoms abnormalities</measure>
    <time_frame>10 days after drug administration</time_frame>
    <description>To evaluate the safety and tolerability after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant vital sign abnormalities</measure>
    <time_frame>10 days after drug administration</time_frame>
    <description>To evaluate the safety and tolerability after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant physical examination abnormalities</measure>
    <time_frame>10 days after drug administration</time_frame>
    <description>To evaluate the safety and tolerability after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant laboratory abnormalities</measure>
    <time_frame>10 days after drug administration</time_frame>
    <description>To evaluate the safety and tolerability after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically significant electrocardiograms (ECGs) abnormalities</measure>
    <time_frame>10 days after drug administration</time_frame>
    <description>To evaluate the safety and tolerability after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum observed concentration (Tmax)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time 0 to 24h (AUC0-24h)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax at steady state (Tss max)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax at steady state (Css max)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmin at steady state (Css min)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration at steady state (Css av)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC at steady state (AUCss)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half-life (t1/2)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance at steady state (CLss/F)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluctuation coefficient (DF)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation ratio (Rac)</measure>
    <time_frame>Day 1(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 hours); Day 5(Pre-dose); Day 6(Pre-dose); Day 7(Pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72 hours) after drug administration</time_frame>
    <description>To evaluate the pharmacokinetics after repeated administrations of CSPCHA115 capsules 100, 200, 400 and 600 mg</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Asthma; Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Cohort A1: CSPCHA115 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSPCHA115 100 mg or placebo administered orally in the fasted state for 7 days.&#xD;
Eight subjects will receive CSPCHA115&#xD;
Two subjects will receive matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2: CSPCHA115 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSPCHA115 200 mg or placebo administered orally in the fasted state for 7 days.&#xD;
Eight subjects will receive CSPCHA115&#xD;
Two subjects will receive matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3: CSPCHA115 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSPCHA115 400 mg or placebo administered orally in the fasted state for 7 days.&#xD;
Eight subjects will receive CSPCHA115&#xD;
Two subjects will receive matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4: CSPCHA115 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSPCHA115 600 mg or placebo administered orally in the fasted state for 7 days.&#xD;
Eight subjects will receive CSPCHA115&#xD;
Two subjects will receive matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSPCHA115 100 mg; Matching placebo 100 mg</intervention_name>
    <description>CSPCHA115 100 mg once daily in the fasted state for 7 days; Matching placebo 100 mg once daily in the fasted state for 7 days.</description>
    <arm_group_label>Cohort A1: CSPCHA115 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSPCHA115 200 mg; Matching placebo 200 mg</intervention_name>
    <description>CSPCHA115 200 mg once daily in the fasted state for 7 days; Matching placebo 200 mg once daily in the fasted state for 7 days.</description>
    <arm_group_label>Cohort A2: CSPCHA115 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSPCHA115 400 mg; Matching placebo 400 mg</intervention_name>
    <description>CSPCHA115 400 mg once daily in the fasted state for 7 days; Matching placebo 400 mg once daily in the fasted state for 7 days.</description>
    <arm_group_label>Cohort A3: CSPCHA115 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CSPCHA115 600 mg; Matching placebo 600 mg</intervention_name>
    <description>CSPCHA115 600 mg once daily in the fasted state for 7 days; Matching placebo 600 mg once daily in the fasted state for 7 days.</description>
    <arm_group_label>Cohort A4: CSPCHA115 600 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 ≤ age ≤ 45 years old, male or female;&#xD;
&#xD;
          -  Bodyweight≥45.0 kg (female) or 50.0 kg (male), 19 kg/m^2 ≤ Body Mass Index（BMI ）≤ 26&#xD;
             kg/m^2;&#xD;
&#xD;
          -  The female subjects are not during pregnancy or lactation; the male subjects have no&#xD;
             sperm donation plan from the signing of the informed consent form to 1 month after the&#xD;
             completion of the study. The subjects and their partners agree to use effective&#xD;
             non-hormonal contraceptives (such as condoms, drug-free IUDs, etc.) from the day&#xD;
             signing the informed consent form to 1 month after the completion of the study, or had&#xD;
             taken permanent contraceptives (such as bilateral tubal ligation, vasectomy, etc.);&#xD;
&#xD;
          -  Subjects voluntarily sign the informed consent form, and are able to complete the&#xD;
             trial according to the protocol;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Those who conform to one of the following provisions shall not be included in the group;&#xD;
&#xD;
          -  A clear history of neurological or mental disorders (including seizures, dementia,&#xD;
             depression or biphasic affective disorders, etc.); immunodeficient or&#xD;
             immunosuppressive diseases, malignant tumor diseases; cardiovascular, liver and&#xD;
             kidney, endocrine, respiratory, blood, digestive system and other chronic diseases;&#xD;
&#xD;
          -  Subjects who underwent large surgical operations within 6 months before signing the&#xD;
             informed consent (such as coronary artery bypass grafting, hepatorenectomy,&#xD;
             nephrectomy, gynecological surgery, etc.), and those with acute neurological,&#xD;
             digestive, respiratory, circulation, endocrine, blood and other systemic diseases&#xD;
             within 3 months before signing the informed consent form may affect the absorption,&#xD;
             distribution, metabolism and excretion of drugs;&#xD;
&#xD;
          -  Subjects with allergic constitutions, or who are allergic to more than 1 drug, or had&#xD;
             other known serious allergic reactions;&#xD;
&#xD;
          -  Subjects who did not meet the health criteria during the screening period, including&#xD;
             abnormal vital signs; QTc interval ≥ 450 ms (male) or 470ms (female), prolongation of&#xD;
             QTc interval, or other abnormal clinical significance of electrocardiogram (ECG); the&#xD;
             results of physical examination, laboratory examination and so on are abnormal and&#xD;
             have clinical significance.&#xD;
&#xD;
          -  One of hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV),&#xD;
             human immunodeficiency virus antibody (Anti-HIV) and Treponema pallidum antibody&#xD;
             (Anti-TP) was positive;&#xD;
&#xD;
          -  Any prescription drugs, non-prescription drugs, biological products, the Chinese&#xD;
             patent medicines, herbs, vitamin dietary supplements, and health-care products (other&#xD;
             than external use), oral long-acting contraceptives or embedded long-acting&#xD;
             contraceptives were used regularly within 2 weeks before the signing of the informed&#xD;
             consent form;&#xD;
&#xD;
          -  A history of alcoholism, or alcohol test positive at screening;&#xD;
&#xD;
          -  The average daily smoking volume was more than 5 within 6 months before signing the&#xD;
             informed consent form;&#xD;
&#xD;
          -  Drug abuse within 1 year before signing the informed consent form, or urine test&#xD;
             positive for drugs at screening;&#xD;
&#xD;
          -  Subjects who were accustomed to excessive caffeine drinks or foods that may affect&#xD;
             drug metabolism within 4 weeks prior to the signing of the informed consent form;&#xD;
&#xD;
          -  Subjects who lost blood or donated more than 200 ml within 8 weeks before signing the&#xD;
             informed consent form, or who planned to donate blood within 1 month after the&#xD;
             completion of the study;&#xD;
&#xD;
          -  Subjects who plan to undergo surgery during the trial period, or those who plan to&#xD;
             take part in strenuous exercise during the trial period;&#xD;
&#xD;
          -  Subjects who are participating in other clinical trials, or who have participated in&#xD;
             clinical trial about any other drugs or devices within 3 months before signing the&#xD;
             informed consent form;&#xD;
&#xD;
          -  Not suitable for this clinical trial judged by the investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuefang Xia</last_name>
    <role>Study Director</role>
    <affiliation>Department of Medicine, CSPC Clinical Development Division</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>November 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CSPCHA115</keyword>
  <keyword>Asthma</keyword>
  <keyword>CRTH2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

